Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as a potent therapeutic option for managing dyslipidemia, particularly in patients who do not achieve target lipid levels with statins alone [207]. The gene discussed is PCSK9; the disease is metabolic syndrome.